García & Bodán has advised Salud Digna, a Mexican health support organisation, in its start-up operations in the Republics of Guatemala and El Salvador, through its first clinical laboratory and imaging units in
Tags :Healthcare area
Gonzalez Calvillo has represented SK Capital Partners in a private investment signing for the acquisition of Apotex Pharmaceutical Holdings, a Canadian pharmaceutical company. The transaction was signed on 22 September 2022 and closed on 1 April 2023, and included
Panamanian law firm Arias Fábrega & Fábrega has advised Gramercy Funds Management and Compass Group in connection with a financing for the acquisition of Hospital Medicadiz, as well as the financing for the
Philippi Prietocarrizosa Ferrero DU & Uría has represented UC Christus in the acquisition of 100% of the shares of the Chilean companies Servicios Médicos Medicien, Laboratorios Medicien, Laboratorio Clínico Medicien Limitada and Inmobiliaria
Clifford Chance has counselled Lenus Capital Partners (Lenus) on financing the acquisition of 100% of Hospital Medicadiz in Ibagué, Colombia. Gramercy Funds Management structured and led the financing of the acquisition, with the participation of Compass
Philippi Prietocarrizosa Ferrero DU & Uría Chile has counselled UC Christus on the acquisition of 100% of the shares of Grupo Medicien from Colmena Salud and Colmena Holding (Colmena). This transaction was signed on 31 January
Ferrere has represented The MARE Group in its start-up operations in Bolivia. The advisory involved the incorporation of the company, installation of commercial and labour issues, as well as obtaining import permits and registrations and
Carey has acted as Chilean counsel to the Spanish medical services company, Atrys Health, in the acquisition of 100% of the shares of Telmed and Prestaciones Médicas e Inversiones Chaxa, Chilean companies specialising in teleradiology.
Paulo Rosito (pictured) is Souto Correa’s newest legal counsel for the Life Sciences and Healthcare area. Rosito has more than 25 years of experience in executive legal positions with traditional pharmaceutical industries, such as Abbott,
